Efficiency and cytotoxicity analysis of cationic lipids-mediated gene transfection into AGS gastric cancer cells
Source abstract
Abstract
In this effort, we provided comparative study on optimization of transfection conditions for AGS human gastric cancer cell line using two commercial non-liposomal cationic lipids. Using reporter vector pEGFP-N1, transfection efficiency of Attractene™ and X-tremeGENE HP™ transfection reagents in terms of cell densities and DNA/reagent ratios was determined in AGS cells by flow cytometry and fluorescence microscopy. In addition, influence of transfection reagents on direct cytotoxicity and cell viability was respectively, measured using lactate dehydrogenase (LDH) leakage and MTT assays. Provided that the transfection rate of 29% and the mean fluorescence intensity of 437.5, the DNA/reagent ratio of 0.4/1.5 was selected as the optimal condition using Attractene™, whereas the optimum condition using X-tremeGENE HP™ was obtained by the ratio of 1/2 with a higher transfection rate of 36.9% and an MFI of 833. Very low direct cytotoxicity (<5% and 6-9% using Attractene™ and X-tremeGENE HP™, respectively) and high cell viability (74.5-95.5% versus 68-75%) showed the biodegradable attribute for both transfection reagents. Altogether, X-tremeGENE HP™ exhibited superiority over Attractene™ as a transfection reagent for AGS cells. In the present research, we have established the optimized protocols for efficient transfection of AGS cells with potential applications in gene function and expression studies as well as gene therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran;
Department of Biology, Faculty of Basic Sciences, Rab-Rashid Higher Education institute, Tabriz, Iran;
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Funding
Tabriz University of Medical Sciences
References (35)
Show source-provided references
1. 10.1016/0140-6736(93)92315-K10.1016/0140-6736(93)92315-K ↗
2. Walthers CM · Biomark Insights · 2015 · 10 · 11
3. 10.3892/mmr.2012.110010.3892/mmr.2012.1100 ↗
4. 10.1016/j.jconrel.2009.01.02210.1016/j.jconrel.2009.01.022 ↗
5. 10.1080/21691401.2017.130721010.1080/21691401.2017.1307210 ↗
6. 10.1038/337387a010.1038/337387a0 ↗
7. 10.1016/j.biomaterials.2012.06.09310.1016/j.biomaterials.2012.06.093 ↗
8. 10.1007/128_2010_6710.1007/128_2010_67 ↗
9. 10.1186/1477-3155-10-710.1186/1477-3155-10-7 ↗
10. 10.1080/1465324080247430710.1080/14653240802474307 ↗
11. Zhao DD · Acta Med Okayama · 1997 · 51 · 149
12. Balasubramaniam RP · Gene Ther · 1996 · 3 · 163
13. 10.1016/j.bbamem.2013.11.01410.1016/j.bbamem.2013.11.014 ↗
14. 10.2174/15672010577437024910.2174/156720105774370249 ↗
15. 10.1080/1537651080189128610.1080/15376510801891286 ↗
16. 10.1007/s00418000022510.1007/s004180000225 ↗
17. 10.1038/sj.gt.330037410.1038/sj.gt.3300374 ↗
18. 10.1016/S0005-2736(02)00545-X10.1016/S0005-2736(02)00545-X ↗
19. 10.2144/96201st0310.2144/96201st03 ↗
20. 10.1007/s00109-002-0368-910.1007/s00109-002-0368-9 ↗
21. Simoes S · Curr Opin Mol Ther · 1999 · 1 · 147
22. 10.1002/med.2009010.1002/med.20090 ↗
23. 10.1038/mt.2009.28110.1038/mt.2009.281 ↗
24. 10.1016/j.ymthe.2004.05.02310.1016/j.ymthe.2004.05.023 ↗
25. Clark PR · Curr Opin Mol Ther · 1999 · 1 · 158
26. 10.2144/00281rr0310.2144/00281rr03 ↗
27. 10.1016/S0003-9861(02)00725-710.1016/S0003-9861(02)00725-7 ↗
28. 10.1016/j.bbamcr.2005.11.00510.1016/j.bbamcr.2005.11.005 ↗
29. 10.1042/BST035006810.1042/BST0350068 ↗
30. 10.3109/21691401.2014.91305410.3109/21691401.2014.913054 ↗
31. 10.1016/S0006-3495(96)79309-810.1016/S0006-3495(96)79309-8 ↗
32. 10.1080/21691401.2017.128249610.1080/21691401.2017.1282496 ↗
33. 10.1016/j.toxlet.2005.07.00110.1016/j.toxlet.2005.07.001 ↗
34. 10.1016/j.ejpb.2004.04.00110.1016/j.ejpb.2004.04.001 ↗
35. 10.1016/0005-2736(90)90017-I10.1016/0005-2736(90)90017-I ↗